• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

    1.381 -0.019 (-1.39%)
    Streaming Delayed Price Updated: 1:32 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 26,193
    Open 1.400
    Bid (Size) 1.380 (200)
    Ask (Size) 1.390 (200)
    Prev. Close 1.400
    Today's Range 1.380 - 1.423
    52wk Range 0.6100 - 5.480
    Shares Outstanding 23,541,824
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ABVC BioPharma Provides Corporate and Structural Update
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    ABVC BioPharma Provides Corporate and Structural Update
    SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“ABVC” or the “Company”), a clinical-stage biopharmaceutical company focused on botanical-derived... 
    Via TheNewswire.com
    Topics Intellectual Property

    Performance

    YTD
    -37.0%
    -37.0%
    1 Month
    -33.3%
    -33.3%
    3 Month
    -45.4%
    -45.4%
    6 Month
    -52.9%
    -52.9%
    1 Year
    +86.1%
    +86.1%

    More News

    Read More
    News headline image
    ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
    Via NewMediaWire
    ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
    Via TheNewswire.com
    News headline image
    ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
    Via NewMediaWire
    ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030
    Via TheNewswire.com
    News headline image
    ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
    Via NewMediaWire
    ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
    Via TheNewswire.com
    News headline image
    ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
    Via NewMediaWire
    Topics Artificial Intelligence
    ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million
    Via TheNewswire.com
    Topics Artificial Intelligence
    News headline image
    ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
    Via NewMediaWire
    News headline image
    ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025
    Via TheNewswire.com
    News headline image
    ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
    Via NewMediaWire
    News headline image
    ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950
    Via TheNewswire.com
    ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
    Via TheNewswire.com
    News headline image
    ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology
    Via NewMediaWire
    News headline image
    ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
    Via NewMediaWire
    ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production
    Via TheNewswire.com
    ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
    Via TheNewswire.com
    News headline image
    ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
    Via NewMediaWire
    News headline image
    ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
    Via NewMediaWire
    ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025
    Via TheNewswire.com
    News headline image
    BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
    Via NewMediaWire
    News headline image
    BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration
    Via TheNewswire.com
    ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal
    Via TheNewswire.com

    Frequently Asked Questions

    Is ABVC BioPharma, Inc. - Common Stock publicly traded?
    Yes, ABVC BioPharma, Inc. - Common Stock is publicly traded.
    What exchange does ABVC BioPharma, Inc. - Common Stock trade on?
    ABVC BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ABVC BioPharma, Inc. - Common Stock?
    The ticker symbol for ABVC BioPharma, Inc. - Common Stock is ABVC on the Nasdaq Stock Market
    What is the current price of ABVC BioPharma, Inc. - Common Stock?
    The current price of ABVC BioPharma, Inc. - Common Stock is 1.381
    When was ABVC BioPharma, Inc. - Common Stock last traded?
    The last trade of ABVC BioPharma, Inc. - Common Stock was at 02/24/26 01:32 PM ET
    What is the market capitalization of ABVC BioPharma, Inc. - Common Stock?
    The market capitalization of ABVC BioPharma, Inc. - Common Stock is 32.50M
    How many shares of ABVC BioPharma, Inc. - Common Stock are outstanding?
    ABVC BioPharma, Inc. - Common Stock has 33M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.